enVVeno Medical Corporation (NVNO) is an Irvine, California–based medical device company focused on advancing treatment options for deep venous disease. The company’s mission centers on elevating the standard of care for patients with severe venous conditions, a market that is driven by the clinical burden and long-term impact of chronic ...enVVeno Medical Corporation (NVNO) is an Irvine, California–based medical device company focused on advancing treatment options for deep venous disease. The company’s mission centers on elevating the standard of care for patients with severe venous conditions, a market that is driven by the clinical burden and long-term impact of chronic venous insufficiency and related venous disorders.
Business-wise, enVVeno Medical operates as a late clinical-stage medtech developer. Rather than manufacturing and selling a broad catalog of consumer products, the company’s value proposition is tied to progressing a pipeline of vascular/venous technologies through clinical and regulatory milestones. This typically requires substantial investment in clinical trials, site activation, investigator/physician engagement, quality systems, and development of the procedural workflow around the device.
Product-wise, enVVeno’s flagship technology historically includes the VenoValve, a specialized replacement venous valve intended for open surgical implantation (with a surgeon-driven placement into the femoral vein). In parallel, the company is developing the enVVe system—positioned as a less invasive, non-surgical, transcatheter approach to venous valve replacement. The enVVe system is described as comprising the enVVe valve, a dedicated delivery mechanism, and supporting accessories, reflecting a product design that is tightly coupled to clinical procedure and device handling.
Cost and bill-of-materials (BOM) considerations for a late-stage medical device company often hinge on custom components, sterilization, delivery system parts, and quality/regulatory-grade materials. While specific BOM line items are not provided here, the company’s device-centric approach implies a cost structure dominated by R&D/clinical development and manufacturing readiness rather than recurring consumer-style overhead.
Financially, companies like enVVeno Medical typically prioritize cash preservation and milestone-based financing during development. The provided dataset indicates measures consistent with a development-stage profile (including negative profitability/FCF-style metrics), which aligns with the reality that late clinical-stage medtech firms may be investing heavily before commercialization.
Key people include CEO and Director Robert A. Berman, along with additional board members listed in the provided information. In terms of “wishes” or near-term priorities implied by the disclosures, the company’s public messaging highlights upcoming clinical milestones (e.g., study enrollment and site activation) and interim data updates—typical catalysts for medtech investors as the technology moves toward potential market authorization.
Overall, enVVeno Medical is building venous valve replacement platforms with the goal of improving patient outcomes, first through established surgical approaches (VenoValve) and increasingly through a transcatheter enVVe system intended to reduce invasiveness and expand procedural adoption.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-19.5M
+10.8%
+6.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-15.6M
+7.7%
-9.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
2.6%
+2.2%
-3.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
13.58x
-34.9%
-1.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
